An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...

Bristol Myers (BMY) Squibb announced that the U.S. FDA granted approval for Opdivo Qvantig injection for subcutaneous use, a combination product of nivolumab co-formulated with recombinant human ...

Findings showed nivolumab/relatlimab did not significantly improve recurrence-free survival compared with nivolumab monotherapy. A phase 3 trial evaluating nivolumab and relatlimab-rmbw (Opdualag ...

In a study of patients with advanced melanoma, the prevalence of cutaneous immune–related adverse events (cirAEs) associated with nivolumab/relatlimab combination therapy was 21.5%, with rash ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer ...